RE:RE:RE:CeoA take out would be a surprise to me, but at this point, anything is possible. IMO, I think the appointment of Taves as the chairman of the board is to prepare the arrival of a decent CEO. The chair of the board reflects a big slice of the company leadership. ie, I doubt any respectable high potential CEO would of been interested in LABS with Pat as chair of the board. Having someone with solid credentials like Taves might actually be a condition for some potential CEO's to join the party.
Also, Taves bought in heavy during offering at .58 cents with .70 cents warrants.There is no rush in striking a deal to sell LABS. At current cash burn, with tax returns scheduled in Q3 (Q2 cc), their cash position should still be above 35M on Q3 financials. With this, they should be able to go dilution free at least until Q1-Q2 2022 financials, maybe past that.
I hate to say it, but STADA or any other deal isn't worth anything until it shows on balance sheet. German market is still in infancy and we all know what happened to CANADA while market grew. Lots of uncertainty. Everywhere.